Boston (December 12, 2023) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company developing novel oncology therapeutics together with drug-specific DRP® companion diagnostics for personalized
Allarity'S Early Phase 2 Stenoparib Data Indicates Clinical Benefit In Women With Advanced Ovarian Cancer Selected With DRP® Companion Diagnostic menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Allarity will present on development ofseveraldrug-specificDRP®companiondiagnostics, and participate in a panel discussion with speakersfrom Merck and Roche
PLOS ONE Publishes Data on Allarity Therapeutics' DRP® Companion Diagnostic for Dovitinib streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Allarity Therapeutics (ALLR) Reports Publication on DRP Companion Diagnostic for Dovitinib streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.